Chiesi Spain acquires the right of commercialization of Prevencor for treatment of cholesterol and prevention of cardiovascular disease

within the framework of the agreement reached between Pfizer and Chiesi Spain

-the prevalence of hypercholesterolemia in the Spanish population is high and is one of the main factors of cardiovascular risk

-Prevencor incorporating a portfolio of Chiesi drugs meana. an injection of turnover exceeding 10% of the current total, reaching the second position in the company’s sales

-the agreement reached with Pfizer highlights the commitment of the Chiesi Group by an active policy of partnerships and agreements with companies with which it shares scientific synergiesstrategic and commercial

-Chiesi Spain reached a volume of business in 2011 of more than 67 million euros

Barcelona, December 2012.- the laboratory pharmacist Chiesi Spain has reached an agreement with Pfizer for marketing Prevencor (atorvastatin), in presentations of 10, 20, 40 and 80 mg. This drug is indicated for the treatment of cholesterol and prevention of cardiovascular disease.

The prevalence of hypercholesterolemia in the Spanish population is high. It is one of the major modifiable cardiovascular risk factors since achieving its reduction, achieved decrease the incidence and mortality from ischemic heart disease and cardiovascular disease.
Prevencor is indicated as add-on therapy to diet in reducing total cholesterol, LDL cholesterol and apoprotein B triglycerides high in adults, adolescents and children aged 10 years with primary hypercholesterolemia, including Familial Hypercholesterolemia (Variant heterozigotica) or combined (mixed) Hyperlipidemia (corresponding to types IIa and IIb of the Fredrickson classification) when the response obtained with diet u other non-pharmacological measures has been inadequate.

It is also indicated for cholesterol-lowering total and LDL cholesterol in adults with Familial Hypercholesterolemia, homozygous, in combined therapy with other treatments lipid lowering (for example, LDL Apheresis) or if these therapies are not available. It also serves for prevention of cardiovascular disease and prevention of cardiovascular events in adult patients considered at high risk, as an adjunctive treatment to the correction of other risk factors.

Prevencor a drug with a great track record

The incorporation of Prevencor to Chiesi drugs portfolio will mean an injection of turnover exceeding 10% of the current total, reaching second place in sales of the company. Chiesi Spain reached a volume of business in 2011 of more than 67 million euros.

Chiesi Spain is today one of the main subsidiaries of the group in terms of turnover. The trajectory of the company in Spain has exceeded all expectations. While in 1995 it ranked 98 in the ranking of pharmaceutical market sales, is currently situated around place 40. This development is mainly due to three factors: the launch of innovative products with a high therapeutic potential obtained from the own r & d, the development of the full potential of its product portfolio, and its successful policy of licensing.

Chiesi Spain has a wide portfolio of products, which are mainly concentrated in three therapeutic areas: cardiovascular, respiratory, and neonatology. as in the rest of the countries in which we are present, the Chiesi Group has an active policy of alliances and agreements with companies with which it shares scientific synergies in Spainstrategic and commercial as it is the case with Pfizer ”, explains Sara Montero, responsible for Business Development of the Spanish subsidiary of Chiesi.

Have the opportunity to launch shortly a product such as Foster Nexthaler ® and the incorporation of another as Prevencor represents a big boost to our company ”, emphasizes.

Chiesi

Laboratories CHIESI is a multi-national pharmaceutical headquartered in Parma (Italy) created more than 75 years ago. In recent years, its policy of impulse of the r & d (which devotes 15% of the turnover) and the new acquisitions have made it possible to reach some sales exceeding 1 billion euros in 2010. It has three (Italy, France and Brazil) production plants and four research centers in Italy, France, Great Britain and United States. It has a strong presence in Europe (including Spain) and worldwide (United States, Brazil, Mexico, Pakistan, China, Russia, Egypt and the Maghreb countries).